Case Report: Infectious prophylaxis in hematological malignancies.
HBV reactivation
myelofibrosis
prophylaxis
ruxolitinib
tenofovir
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
02
2023
accepted:
17
04
2023
medline:
18
5
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
epublish
Résumé
Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomized data are available to strongly recommend HBV prophylaxis in these patients. Here, we report a case of primary myelofibrosis and past serological evidence of HBV infection, treated with ruxolitinib and concomitant lamivudine, developing HBV reactivation due to premature withdrawal of prophylaxis. This case underlines the potential need for persistent HBV prophylaxis in the setting of ruxolitinib treatment.
Identifiants
pubmed: 37197426
doi: 10.3389/fonc.2023.1163175
pmc: PMC10183604
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1163175Informations de copyright
Copyright © 2023 Passucci, Masucci, Paoletti, Ielo, Costa, Carmosino, Scalzulli, Martelli, Gentile and Breccia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Hematol. 2022 Sep;101(9):2081-2086
pubmed: 35488090
Biomark Insights. 2016 Apr 21;10(Suppl 3):55-68
pubmed: 27127405
Haematologica. 2006 Apr;91(4):554-7
pubmed: 16585021
Ann Hematol. 2015 Sep;94(9):1441-50
pubmed: 26193852
Front Med (Lausanne). 2022 Jan 14;8:770124
pubmed: 35096867
World J Gastroenterol. 2016 Jul 28;22(28):6484-500
pubmed: 27605883
Br J Haematol. 2019 Nov;187(3):286-295
pubmed: 31468506
Future Oncol. 2015;11(5):719-33
pubmed: 25757677
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Blood. 2013 Aug 22;122(8):1395-8
pubmed: 23838352
JGH Open. 2021 Aug 19;5(9):1085-1091
pubmed: 34584979
J Viral Hepat. 2015 Mar;22(3):346-52
pubmed: 25220947
Clin Microbiol Infect. 2017 Dec;23(12):935-940
pubmed: 28668466
Haematologica. 2019 Mar;104(3):435-443
pubmed: 30733266